Perspective Therapeutics, Inc. income statement

In fiscal 2023, Perspective Therapeutics, Inc. reported revenue of $1.4m, operating income of −$40.9m (a -2855.0% margin) and net income of −$46.5m, or −$1.74 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Perspective Therapeutics, Inc.: income statement, annual
Fiscal year	2011Jun 2011	2012Jun 2012	2013Jun 2013	2014Jun 2014	2015Jun 2015	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Dec 2022	2023Dec 2023
Revenue	5	5	5	4	5	5	5	6	7	10	10	0	1
Cost of revenue	—	—	—	—	—	5	4	4	4	5	5	—	—
Gross profit	1	1	0	−0	0	0	1	2	3	5	5	—	1
Research and development	1	1	1	1	1	1	1	2	1	1	1	—	21
Selling and marketing	1	1	1	1	1	1	2	3	3	3	2	—	—
General and administrative	2	2	2	2	2	4	4	4	4	5	5	—	21
Operating income	−3	−4	−4	−5	−4	−5	−6	−7	−5	−3	−3	—	−41
Interest expense	—	—	0	0	0	0	0	—	—	—	—	—	0
Income before tax	—	—	—	—	—	—	—	—	—	—	—	—	−40
Income tax	—	—	—	0	0	0	0	0	0	0	0	—	−3
Net income	−3	−3	−4	−6	−4	−5	−6	−7	−5	−3	−3	—	−47
Diluted EPS	−$1.10	−$1.20	−$0.11	−$1.60	−$0.70	−$0.90	−$1.10	−$1.20	−$0.80	−$0.05	−$0.30	—	−$1.74
Diluted shares (average)	3m	3m	3m	4m	5m	6m	6m	6m	7m	7m	10m	—	27m
EBITDA	−2	−3	−3	−4	−4	−5	−6	−7	−5	−3	−3	—	−40

US$ millions unless shown otherwise. Fiscal quarters.

Perspective Therapeutics, Inc.: income statement, quarterly
Quarter	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023
Revenue	3	3	2	2	2	2	2	−5
Cost of revenue	1	2	1	1	2	2	1	—
Gross profit	1	1	0	−0	0	0	1	−0
Research and development	1	1	1	−0	3	5	6	7
Selling and marketing	1	1	1	1	1	1	1	—
General and administrative	2	2	3	2	7	5	4	5
Operating income	−1	−2	−4	−1	−10	−10	−10	−12
Interest expense	0	0	0	0	0	0	0	0
Income before tax	−1	−2	−4	−1	−9	−9	−10	−12
Income tax	0	0	0	0	−11	0	0	8
Net income	−1	−2	−4	−3	−0	−11	−10	−25
Diluted EPS	—	—	—	—	$0.00	−$0.40	−$0.37	−$0.91
EBITDA	−1	−2	−4	−1	−10	−9	−9	−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Perspective Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Perspective Therapeutics, Inc.